drugset
drugset / Trial / NCT05047536

KZR-261 in Subjects With Advanced Solid Malignancies

NCT05047536 ↗

Phase 1 Terminated 61 enrolled Kezar Life Sciences, Inc.
NaSingle-groupOpen-labelTreatment

Summary

A first-in-human, open-label, multicenter, Phase 1 study of KZR-261 designed to assess the safety and tolerability, preliminary anti-tumor activity, and pharmacokinetics (PK) of KZR-261, as well as identify the recommended Phase 2 dose (RP2D). The study comprised a Part 1 (Dose Escalation) and a Part 2 (2A Dose Expansion and 2B Dose Optimization) in solid organ tumors (melanoma/uveal melanoma, mesothelioma, colorectal cancer, castration-resistant prostate cancer, and "All-Tumors").

Timeline

Start
2021-09-30
Primary completion
2025-01-17
Completion
2025-01-17

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision.”

Drugs

EvaluationDrugModalityDoseRoute
Subject KZR-261 Small molecule 1.8 mg/m2 Intravenous

Indications

No indication recorded.